At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 38 target
Drug / intervention
Autologous CD7-targeting CAR T cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial of S101 Autologous CAR-T Cell Injection for the Treatment of CD7-Positive Relapsed or Refractory T-Lymphoblastic Lymphoma/Leukemia (T-LBL/ALL).
In Brief
A Phase 2 clinical trial evaluating Autologous CD7-targeting CAR T cells for T Lymphoblastic Leukemia/Lymphoma. Not yet recruiting, targeting 38 participants.
Detailed Summary
To Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL/ALL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsT Lymphoblastic Leukemia/Lymphoma
Countries--
Collaborators--
Timeline
Phase 2Not Yet Recruiting
202620272028
First PostedNov 2025
Enrollment StartNov 2025
TodayJul 2026
Primary CompletionSep 2026
Study CompletionJun 2028
First PostedNov 24, 2025
Enrollment StartNov 28, 2025
Primary CompletionSep 30, 2026
Study CompletionJun 30, 2028
TodayJul 1, 2026
Enrollment to primary: 10 monthsPosted 7 months agoPrimary completion in 3 months
Interventions
Autologous CD7-targeting CAR T cellsbiological
Autologous CD7-targeting CAR T cells, dosage 2\*10\^6/kg, intravenous injection once